Fintel reports that on May 8, 2023, Stifel maintained coverage of Arvinas (NASDAQ:ARVN) with a Buy recommendation.
Analyst Price Forecast Suggests 208.85% Upside
As of April 24, 2023, the average one-year price target for Arvinas is 76.19. The forecasts range from a low of 30.30 to a high of $158.55. The average price target represents an increase of 208.85% from its latest reported closing price of 24.67.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Arvinas is 120MM, a decrease of 12.34%. The projected annual non-GAAP EPS is -6.20.
What is the Fund Sentiment?
There are 448 funds or institutions reporting positions in Arvinas. This is a decrease of 7 owner(s) or 1.54% in the last quarter. Average portfolio weight of all funds dedicated to ARVN is 0.17%, a decrease of 38.28%. Total shares owned by institutions decreased in the last three months by 0.21% to 54,004K shares. The put/call ratio of ARVN is 0.33, indicating a bullish outlook.
What are Other Shareholders Doing?
Avidity Partners Management holds 4,950K shares representing 9.27% ownership of the company. In it's prior filing, the firm reported owning 4,344K shares, representing an increase of 12.25%. The firm decreased its portfolio allocation in ARVN by 6.62% over the last quarter.
EcoR1 Capital holds 3,123K shares representing 5.85% ownership of the company. No change in the last quarter.
Price T Rowe Associates holds 2,368K shares representing 4.43% ownership of the company. In it's prior filing, the firm reported owning 2,180K shares, representing an increase of 7.95%. The firm decreased its portfolio allocation in ARVN by 17.97% over the last quarter.
Bellevue Group holds 2,150K shares representing 4.03% ownership of the company. In it's prior filing, the firm reported owning 2,191K shares, representing a decrease of 1.88%. The firm decreased its portfolio allocation in ARVN by 35.88% over the last quarter.
Jpmorgan Chase holds 1,967K shares representing 3.68% ownership of the company. In it's prior filing, the firm reported owning 2,092K shares, representing a decrease of 6.34%. The firm decreased its portfolio allocation in ARVN by 33.62% over the last quarter.
Arvinas Background Information
(This description is provided by the company.)
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and "undruggable" targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.